Confindustria Emilia Logo
welcome to the manufacturing heart of Europe
Logo Confindustria Emilia - Area Centro
Search
Logo Confindustria Emilia - Area Centro
LINGUE
Italiano Logo Confindustria Emilia - Italiano
English Logo Confindustria Emilia - English
Deutsch Logo Confindustria Emilia - Deutsch
Français Logo Confindustria Emilia - Français
Español Logo Confindustria Emilia - Español
welcome to the manufacturing heart of Europe
Logo Confindustria Emilia - Area Centro
MENù

Association

  1. About us
  2. Governance
  3. Associated Companies
  4. Organisation
  5. The Supply Chains

Contact us

  1. Contacts

News from the World

  1. Opportunities and Business Trends

Social media

Facebook
Twitter
Youtube
Linkedin
Instagram
Logo app Confindustria Emilia
Logo Farete

3.200 companies perform
in 20 supply chain for
a total 180,000 employees

ABOUT US

News from the world

EXPLORE THE MAP

 World ico
UK Taylor Wimpey lifts profit target after building record number of homes Company constructed more than 7,300 houses in first half of 2021 after Covid hit earnings a year earlier
UK Levelling-up requires trillions not billions, economists warn The British government’s flagship levelling-up policy risks falling far short of what’s required, economists have warned.
WORLD Climate crisis to shrink G7 economies twice as much as Covid-19, says research The economies of rich countries will shrink by twice as much as they did in the Covid-19 crisis if they fail to tackle rising greenhouse gas emissions, according to research.
USA White House warns companies to step up cybersecurity The White House warned corporate executives and business leaders on Thursday to step up security measures to protect against ransomware attacks after intrusions at a meatpacking company and an oil pipeline.
switch

From outside to inside

Discover the presence of Confindustria Emilia or business opportunities and risk in the world

From inside to outside Opportunity Risk

Fare News
 
DIGITAL SUPPLY CHAIN CRIF once again among the IDC FinTech Rankings top 100 CRIF - a global company specialising in credit and business information systems as well as advanced digital solutions for business development and open banking - is in 53rd place in the IDC FinTech Rankings 2021.
THE AGREEMENT Alfasigma acquires the European licence for bentracimab from PhaseBio Alfasigma has entered into an exclusive licencing with PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), for the commercialisation of bentracimab in 49 countries between Europe and other key markets. PhaseBio is a biopharmaceutical company focused on the development and commercialisation of novel therapies for cardiopulmonary diseases. The agreement covers the countries of the European Union and the European Economic Area, as well as the United Kingdom, Russia, Ukraine and other countries of the Commonwealth of Independent States
PHARMACEUTICAL Opocrin among funders of Swedish study on molecule that facilitates onset of childbirth An important announcement involving Italy and Sweden: Opocrin, a pharmaceutical company from Modena specialising in the production of heparin and other active ingredients, welcomes the conclusion of phase 2b trial of a modified heparin molecule tafoxiparin. The trial was conducted by the Swedish pharmaceutical company Dilafor, in which Opocrin is the second largest shareholder with a 22% stake
AUTOMOTIVE CRP Technology introduces Windform® RS, the new composite material CRP Technology launches Windform® RS, the carbon fibre filled composite material with unparalleled and exceptional mechanical characteristics, capable of superior performance, on the Additive Manufacturing market.
THE AWARD Eurosets receives the Frost & Sullivan recognition for ECMOLife considered as the most innovative biomedical product of 2021 Eurosets, an Italian company from Medolla (in the province of Modena), specialised in the design, production and marketing of biomedical devices, has been awarded with the Global New Product Innovation 2021 award by Frost & Sullivan for ECMOLife, an innovative device for the ECMO therapies capable of temporarily replacing the function of the heart and lungs